| pubmed-article:8205562 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8205562 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8205562 | lifeskim:mentions | umls-concept:C0699885 | lld:lifeskim |
| pubmed-article:8205562 | lifeskim:mentions | umls-concept:C0015980 | lld:lifeskim |
| pubmed-article:8205562 | lifeskim:mentions | umls-concept:C2709199 | lld:lifeskim |
| pubmed-article:8205562 | lifeskim:mentions | umls-concept:C1752435 | lld:lifeskim |
| pubmed-article:8205562 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:8205562 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8205562 | pubmed:dateCreated | 1994-7-8 | lld:pubmed |
| pubmed-article:8205562 | pubmed:abstractText | We have investigated the effect of interferon beta (INF beta) on the natural killer (NK) cytotoxic activity of peripheral blood mononuclear cells (PBMC) from patients with superficial and infiltrative transitional-cell carcinoma of the bladder (TCC) against both NK-sensitive and NK-resistant target cells. The normal NK activity found in PBMC from these patients can be significantly enhanced by short-term incubation (18 h) with INF beta (P < 0.05). The depressed NK cytotoxic activity found in PBMC from patients with infiltrative TCC can also be significantly enhanced, but not normalized, by short-term incubation with INF beta (P < 0.05). In kinetic studies we found that the maximal levels of the INF beta-promoted cytotoxic activity against NK-sensitive and against NK-resistant target cells in PBMC from TCC patients were reached after 18 h of culture. Short-term-INF beta-incubated PBMC from patients with TCC of the bladder also showed marked cytotoxic activity against NK-resistant target cells. The effector cells of the INF beta-induced cytotoxic activity in PBMC from patients with TCC were CD16+ CD3- NK cells. This cytotoxic inducer effect of INF beta synergized with that of interleukin-2. In conclusion, INF beta can enhance the NK activity of PMBC from patients with TCC of the bladder. | lld:pubmed |
| pubmed-article:8205562 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8205562 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205562 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8205562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205562 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8205562 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8205562 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:8205562 | pubmed:author | pubmed-author:OlivierCC | lld:pubmed |
| pubmed-article:8205562 | pubmed:author | pubmed-author:ManzanoLL | lld:pubmed |
| pubmed-article:8205562 | pubmed:author | pubmed-author:Alvarez-MonMM | lld:pubmed |
| pubmed-article:8205562 | pubmed:author | pubmed-author:MoltóLL | lld:pubmed |
| pubmed-article:8205562 | pubmed:author | pubmed-author:CarballidoJJ | lld:pubmed |
| pubmed-article:8205562 | pubmed:author | pubmed-author:LapeñaPP | lld:pubmed |
| pubmed-article:8205562 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8205562 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:8205562 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8205562 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8205562 | pubmed:pagination | 406-10 | lld:pubmed |
| pubmed-article:8205562 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:meshHeading | pubmed-meshheading:8205562-... | lld:pubmed |
| pubmed-article:8205562 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8205562 | pubmed:articleTitle | Interferon beta enhances the natural killer activity of patients with bladder carcinoma. | lld:pubmed |
| pubmed-article:8205562 | pubmed:affiliation | Department of Medicine, Hospital Universitario Principe de Asturias, Universidad de Alcalá de Henares, Madrid, Spain. | lld:pubmed |
| pubmed-article:8205562 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8205562 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
